

9. (once amended) Method according to claim 1 or 2 (one of the previous claims), wherein the fusion protein contains a second specific proteolytic cleavage site for the removal of one or more of the other affinity tags.

10. (once amended) Method according to claim 1 or 2 (one of the previous claims), wherein one of the affinity tags consists of at least one calmodulin binding peptide.

14. (once amended) A [N]ucleic acid coding for a fusion protein [according to claim 12 or 13], the fusion protein comprising at least one polypeptide or subunit of a protein complex fused to at least two different affinity tags, wherein one of the affinity tags consists of at least one IgG binding domain of Staphylococcus protein A.

15. (once amended) A [V]ector comprising a nucleic acid [according to claim 14] under the control of sequences facilitating the expression of a fusion protein [according to claim 12 or 13], the fusion protein comprising at least one polypeptide or subunit of a protein complex fused to at least two different affinity tags, wherein one of the affinity tags consists of at least one IgG binding domain of Staphylococcus protein A.

16. (once amended) A [C]ell containing a nucleic acid coding for a fusion protein [according to claim 14] or a vector [according to claim 15] comprising a nucleic acid under the control of sequences facilitating the expression of a fusion protein, the fusion protein comprising at least one polypeptide or subunit of a protein complex fused to at least two different affinity tags, wherein one of the affinity tags

comprises at least one IgG binding domain of Staphylococcus aureus protein A.

19. (once amended) A [B] reagent kit comprising:
a nucleic acid coding for a fusion protein [according to claim 14] or a vector [according to claim 15, 16 or 17] for the expression of a fusion protein [according to claim 12 or 13], wherein the fusion protein comprising at least one polypeptide or subunit of a protein complex fused to at least two different affinity tags, wherein one of the affinity tags consists of at least one IgG binding domain of Staphylococcus protein A; and

support materials each capable of binding at least one [of the] affinity tag[s].

PLEASE ADD THE FOLLOWING NEW CLAIMS.

23. A nucleic acid according to claim 14 or 15 wherein the fusion protein further comprises a specific proteolytic cleavage site.

24. The reagent kit of claim 19 wherein the vector includes a nucleic acid under the control of sequences facilitating the expression of fusion proteins.

25. The reagent kit of claim 19 wherein the vector comprising heterologous nucleic acid sequences in form of one or more cassettes each comprising at least two different affinity tags one consisting of one or more IgG binding domains of Staphylococcus aureus protein A, and at least one polynucleotide linker for the insertion of further nucleic acids.

26. The reagent kit of claim 15 wherein the kit is comprised of a first reagent for use in the detection in form of two or more cassettes each comprising at least one of different affinity tags one consisting of one or more IgG binding domains of Staphylococcus aureus protein A, and at least one polynucleotide linker for the further insertion of further nucleic acids.

27. A method for detection and/or purification of substances capable of complexing with fusion proteins, the method comprising contacting the fusion proteins with a sample and detecting and/or purifying substances capable of complexing with the fusion protein.

28. A method for detection and/or purification of cells and/or cell organelles expressing a fusion protein on their surface, the method comprising contacting the cells and/or cell organelles expressing a fusion protein on their surface with a substance capable of binding with the fusion protein, and detecting and/or purifying the cell and/or cell organelles expressing the fusion protein.

REMARKS

Upon entry of this Preliminary Amendment, claims 9, 11, 14-15, 18, and 19 have been amended, claims 23-26 have been added, claims 21 and 22 have been canceled, and claims 1-22 and 23-26 are pending. The aforementioned amendments are matters of form, and this Preliminary Amendment merely places this application in a more standard U.S. format. Entry of the amendment is respectfully requested.